HC Wainwright Lifts Earnings Estimates for Vir Biotechnology

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities research analysts at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Vir Biotechnology in a research note issued to investors on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.54) per share for the quarter, up from their previous forecast of ($0.84). HC Wainwright currently has a "Buy" rating and a $110.00 target price on the stock. The consensus estimate for Vir Biotechnology's current full-year earnings is ($3.92) per share. HC Wainwright also issued estimates for Vir Biotechnology's Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.48) EPS, Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.23) EPS, FY2027 earnings at ($2.28) EPS, FY2028 earnings at ($1.78) EPS and FY2029 earnings at ($1.37) EPS.

Several other research firms also recently weighed in on VIR. The Goldman Sachs Group cut their target price on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Needham & Company LLC reaffirmed a "buy" rating and issued a $14.00 price objective on shares of Vir Biotechnology in a research report on Thursday. Finally, Barclays upped their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Vir Biotechnology presently has a consensus rating of "Moderate Buy" and an average target price of $32.86.

Vir Biotechnology Trading Down 2.4%

Shares of NASDAQ VIR traded down $0.11 during trading hours on Thursday, hitting $4.50. 1,383,910 shares of the company traded hands, compared to its average volume of 1,383,983. The stock has a market capitalization of $622.07 million, a price-to-earnings ratio of -1.15 and a beta of 1.36. The company's 50 day moving average price is $5.72 and its 200 day moving average price is $7.68. Vir Biotechnology has a 12 month low of $4.32 and a 12 month high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.05). The company had revenue of $3.03 million for the quarter, compared to the consensus estimate of $8.59 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business's revenue for the quarter was down 94.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.48) EPS.

Insider Transactions at Vir Biotechnology

In other news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the transaction, the executive vice president now owns 79,460 shares of the company's stock, valued at approximately $726,264.40. This represents a 8.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Backer Marianne De sold 79,712 shares of the company's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total value of $474,286.40. Following the sale, the chief executive officer now owns 769,505 shares of the company's stock, valued at $4,578,554.75. This trade represents a 9.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 15.60% of the company's stock.

Institutional Investors Weigh In On Vir Biotechnology

Hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vir Biotechnology during the 4th quarter worth $42,000. GAMMA Investing LLC grew its stake in shares of Vir Biotechnology by 524.3% during the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company's stock worth $46,000 after acquiring an additional 5,972 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Vir Biotechnology during the fourth quarter valued at about $60,000. PNC Financial Services Group Inc. raised its position in shares of Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after purchasing an additional 1,999 shares during the last quarter. Finally, KBC Group NV raised its position in shares of Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock valued at $66,000 after purchasing an additional 5,177 shares during the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).